ICICI Direct's research report on Alembic Pharma
Alembic Pharma operates in international generics (54%), domestic branded (28%) and API (18%).Exports contribute 69% of sales (US~74%), domestic contributes 31% of sales (Chronic~69% & Acute~31%) It has filed 212 ANDA and has 146 approvals with 94 product launches
Outlook
We maintain our HOLD rating on the stock We value Alembic at Rs 885 i.e. 20x P/E on FY23E EPS
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
